GlassScriptPhysician profile
Cheryl A Harth
NPI 1407894413
$18,053.44
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $2,843.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,400.84 | 2019-2020 | |
| Eisai INC. | $5,201.79 | 2019-2020 | |
| Seagen INC. | $2,155.32 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $459.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $267.28 | 2019-2020 | |
| Tesaro, INC. | $238.47 | 2019 | |
| Janssen Biotech, INC. | $229.11 | 2019 | |
| Abbvie INC. | $227.30 | 2019 | |
| Pfizer INC. | $141.83 | 2019 | |
| Astellas Pharma US INC | $135.02 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Daiichi Sankyo INC. | $122.22 | 2020 | |
| Puma Biotechnology, INC. | $121.41 | 2019 | |
| Clovis Oncology, INC. | $118.22 | 2019 | |
| Incyte Corporation | $116.22 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $115.85 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $113.29 | 2019 | |
| Genentech, INC. | $109.91 | 2019 | |
| Heron Therapeutics, INC. | $109.83 | 2019 | |
| Jazz Pharmaceuticals INC. | $86.57 | 2019 | |
| Siemens Medical Solutions USA, INC. | $75.32 | 2019 | |
| Amgen INC. | $74.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.18 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Harth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.